332593

(2-Hidroxipropil)-β-ciclodextrina

average M_w ~1,380

• Sinónimos: (2-Hydroxypropyl)-beta-cyclodextrin
• Número de CAS: 128446-35-5
• EC Number: 420-920-1
• UNSPSC Code: 12352302
• PubChem Substance ID: 24859909
• NACRES: NA.22

Propiedades

• form: powder
• optical activity: [α]26/D +139°, c = 1 in H₂O
• mol wt: average M_w ~1,380
• extent of labeling: 0.6 molar substitution
• mp: 278 °C (dec.)
• SMILES string: CC(O)COCC1OC2OC3C(COCC(C)O)OC(OC4C(COCC(C)O)OC(OC5C(COCC(C)O)OC(OC6C(COCC(C)O)OC(OC7C(COCC(C)O)OC(OC8C(COCC(C)O)OC(OC1C(OCC(C)O)C2OCC(C)O)C(OCC(C)O)C8OCC(C)O)C(OCC(C)O)C7OCC(C)O)C(OCC(C)O)C6OCC(C)O)C(OCC(C)O)C5OCC(C)O)C(OCC(C)O)C4OCC(C)O)C(OCC(C)O)C3OCC(C)O
• InChI: 1S/C63H112O42/c1-22(64)8-85-15-29-50-36(71)43(78)57(92-29)100-51-30(16-86-9-23(2)65)94-59(45(80)38(51)73)102-53-32(18-88-11-25(4)67)96-61(47(82)40(53)75)104-55-34(20-90-13-27(6)69)98-63(49(84)42(55)77)105-56-35(21-91-14-28(7)70)97-62(48(83)41(56)76)103-54-33(19-89-12-26(5)68)95-60(46(81)39(54)74)101-52-31(17-87-10-24(3)66)93-58(99-50)44(79)37(52)72/h22-84H,8-21H2,1-7H3/t22?,23?,24?,25?,26?,27?,28?,29-,30-,31?,32?,33?,34?,35?,36?,37-,38?,39-,40+,41+,42+,43?,44+,45?,46+,47+,48+,49+,50+,51+,52-,53-,54-,55-,56-,57+,58-,59+,60-,61-,62-,63-/m1/s1
• InChI key: ODLHGICHYURWBS-RYJYQAAZSA-N

Descripción

General description

(2-Hydroxypropyl)-β-cyclodextrin (HP-β-CD) is a beta-cyclodextrin and hydroxyalkyl derivative and is widely used as a chiral solvent, phase transfer catalyst, and host molecule in organic synthesis. HP-β-CD can form inclusion complexes with guest molecules, which can help enhance the solubility, stability, and bioavailability of the guest molecule. It is an alternative to α-, β- and γ-cyclodextrin and exhibits a higher water solubility. HP-β-CD is commonly used as a drug solubilizer.

Application

HP-β-CD can be used:

• As an additive in the separation of amino acids and lactic acids based on the coordination interactions between Cu²⁺ ions and analytes.
• As a chiral selector in capillary electrophoresis, enabling the robust separation of diastereomeric derivatives of aspartic acid for analysis.
• As a reagent to improve water solubility and anti-proliferative activity of pyrazolo[3,4-d] pyrimidines.
• As formulation vehicle. It increases water solubility of the drug for successful delivery of medical agents to a biological system.
• To increase the solubility of ropivacaine (RVC) upon complexation, which in turn enhances the pharmacological activity of RVC.
• To increase the aqueous solubility of naproxen (NAP) in presence of polyvinylpyrrolidone (PVP).
• As a template in the synthesis of hollow spherical copper sulfide nanoparticle assemblies.

La solubilidad de los fármacos lipófilos aumenta linealmente con la concentración de hidroxipropil-β-ciclodextrina (HBC) en disolución acuosa debido al complejo entre la HBC y el fármaco. Este complejo tipo huésped-anfitrión se forma entre el fármaco y la cavidad no polar de la HBC que tiene como consecuencia una mayor solubilidad. Las disoluciones pueden liofilizarse para producir polvos libremente solubles. No tóxico en conejos ni ratones.

Información de seguridad

• Storage Class: 13 - Non Combustible Solids
• wgk_germany: WGK 1
• flash_point_f: >752.0 °F
• flash_point_c: > 400 °C
• ppe: Eyeshields, Gloves, type N95 (US)